Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Clinical Immunology
Published in: Journal of Clinical Immunology 6/2006

01-11-2006

Programmed Death-1 Gene Polymorphisms in Patients With Systemic Lupus Erythematosus in Taiwan

Authors: SHU-CHEN WANG, YI-JING CHEN, TSAN-TENG OU, CHENG-CHIN WU, WEN-CHAN TSAI, HONG-WEN LIU, JENG-HSIEN YEN

Published in: Journal of Clinical Immunology | Issue 6/2006

Login to get access

Abstract

To investigate the role of programmed cell death-1 (PD-1) gene polymorphisms in the development of systemic lupus erythematosus (SLE) in Taiwan, 109 patients with SLE and 100 healthy controls were enrolled in this study. The PD-1 gene polymorphisms were determined by the method of polymerase chain reaction/restriction fragment length polymorphism. This study showed that the genotype distributions of PD-1 7209 C/T polymorphisms were significantly different between the patients with SLE and controls (P=0.002, Pc=0.018). The frequencies of the PD-1 7209 C/C genotype and PD-1 7209 C allele were significantly higher in the patients with SLE than those of the controls (P=0.001, OR=2.6, 95% CI=1.5–4.6, and P=0.002, OR=2.1, 95% CI=1.3–3.4, Pc=0.018, respectively). Moreover, the association of PD-1 7209 C with susceptibility to SLE was independent of the PD-1 ligand. This study also showed that the PD-1-536 A 7146 G 7209 C 7499 G haplotype was associated with the development of SLE in Taiwan.
Literature
1.
Tsao BP: Update on human systemic lupus erythematosus genetics. Curr Opin Rheumatol 16(5):513–521, 2004PubMedCrossRef
2.
Prokunina L, Alarcon-Riquelme M: The genetic basis of systemic lupus erythematosus—Knowledge of today and thoughts for tomorrow. Hum Mol Genet 13 (Special Issue 1):R143–148, 2004PubMedCrossRef
3.
Moser KL, Neas BR, Salmon JE et al.: Genome scan of human systemic lupus erythematosus: Evidence for linkage on chromosome 1q in African-American pedigrees. Proc Natl Acad Sci USA 95(25):14869–14874, 1998PubMedCrossRef
4.
Croker JA, Kimberly RP: Genetics of susceptibility and severity in systemic lupus erythematosus. Curr Opin Rheumatol 17(5):529–537, 2005PubMedCrossRef
5.
Ishida Y, Agata Y, Shibahara K, Honjo T: Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11(11):3887–3895, 1992PubMed
6.
Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T: PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci USA 98(24):13866–13871, 2001PubMedCrossRef
7.
Freeman GJ, Long AJ, Iwai Y et al.: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192(7):1027–1034, 2000PubMedCrossRef
8.
Latchman Y, Wood CR, Chernova T et al.: PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2(3):261–268, 2001PubMedCrossRef
9.
Nishimura H, Nose M, Hiai H, Minato N, Honjo T: Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11(2):141–151, 1999PubMedCrossRef
10.
Wang J, Yoshida T, Nakaki F, Hiai H, Okazaki T, Honjo T: Establishment of NOD-Pdcd1−/− mice as an efficient animal model of type I diabetes. Proc Natl Acad Sci USA 102(33):11823–11828, 2005PubMedCrossRef
11.
Ansari MJ, Salama AD, Chitnis T et al.: The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 198(1):63–69, 2003PubMedCrossRef
12.
Nishimura H, Okazaki T, Tanaka Y et al.: Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291(5502):319–322, 2001PubMedCrossRef
13.
Okazaki T, Tanaka Y, Nishio R et al.: Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 9(12):1477–1483, 2003PubMedCrossRef
14.
Lindqvist AK, Steinsson K, Johanneson B et al.: A susceptibility locus for human systemic lupus erythematosus (hSLE1) on chromosome 2q. J Autoimmun 14(2):169–178, 2000PubMedCrossRef
15.
Magnusson V, Lindqvist AK, Castillejo-Lopez C et al.: Fine mapping of the SLEB2 locus involved in susceptibility to systemic lupus erythematosus. Genomics 70(3):307–314, 2000PubMedCrossRef
16.
Prokunina L, Castillejo-Lopez C, Oberg F et al.: A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 32(4):666–669, 2002PubMedCrossRef
17.
Ferreiros-Vidal I, Gomez-Reino JJ, Barros F et al.: Association of PDCD1 with susceptibility to systemic lupus erythematosus: Evidence of population-specific effects. Arthritis Rheum 50(8):2590–2597, 2004PubMedCrossRef
18.
Johansson M, Arlestig L, Moller B, Rantapaa-Dahlqvist S: Association of a PDCD1 polymorphism with renal manifestations in systemic lupus erythematosus. Arthritis Rheum 52(6):1665–1669, 2005PubMedCrossRef
19.
Prokunina L, Padyukov L, Bennet A et al.: Association of the PD-1.3A allele of the PDCD1 gene in patients with rheumatoid arthritis negative for rheumatoid factor and the shared epitope. Arthritis Rheum 50(6):1770–1773, 2004PubMedCrossRef
20.
Kong EK, Prokunina-Olsson L, Wong WH et al.: A new haplotype of PDCD1 is associated with rheumatoid arthritis in Hong Kong Chinese. Arthritis Rheum 52(4):1058–1062, 2005PubMedCrossRef
21.
Lin SC, Yen JH, Tsai JJ et al.: Association of a programmed death 1 gene polymorphism with the development of rheumatoid arthritis, but not systemic lupus erythematosus. Arthritis Rheum 50(3):770–775, 2004PubMedCrossRef
22.
Nielsen C, Hansen D, Husby S, Jacobsen BB, Lillevang ST: Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes. Tissue Antigens 62(6):492–497, 2003PubMedCrossRef
23.
Kroner A, Mehling M, Hemmer B et al.: A PD-1 polymorphism is associated with disease progression in multiple sclerosis. Ann Neurol 58(1):50–57, 2005PubMedCrossRef
24.
Prokunina L, Gunnarsson I, Sturfelt G et al.: The systemic lupus erythematosus-associated PDCD1 polymorphism PD1.3A in lupus nephritis. Arthritis Rheum 50(1):327–328, 2004PubMedCrossRef
25.
Chou WC, Liao KW, Lo YC, Jiang SY, Yeh MY, Roffler SR: Expression of chimeric monomer and dimer proteins on the plasma membrane of mammalian cells. Biotechnol Bioeng 65(2):160–169, 1999PubMedCrossRef
26.
Choi S, Lee E, Kwon S et al.: Transmembrane domain-induced oligomerization is crucial for the functions of syndecan-2 and syndecan-4. J Biol Chem 280(52):42573–42579, 2005PubMedCrossRef
27.
Bourguignon LY, Singer SJ: Transmembrane interactions and the mechanism of capping of surface receptors by their specific ligands. Proc Natl Acad Sci USA 74(11):5031–5035, 1977PubMedCrossRef
Metadata
Title
Programmed Death-1 Gene Polymorphisms in Patients With Systemic Lupus Erythematosus in Taiwan
Authors
SHU-CHEN WANG
YI-JING CHEN
TSAN-TENG OU
CHENG-CHIN WU
WEN-CHAN TSAI
HONG-WEN LIU
JENG-HSIEN YEN
Publication date
01-11-2006
Published in
Journal of Clinical Immunology / Issue 6/2006
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-006-9048-9

Other articles of this Issue 6/2006

Journal of Clinical Immunology 6/2006 Go to the issue

OriginalPaper

Upregulation of Mitochondrial Gene Expression in PBMC from Convalescent SARS Patients

Original Paper

Type I Interferons Attenuate T Cell Activating Functions of Human Mast Cells by Decreasing TNF-α Production and OX40 Ligand Expression While Increasing IL-10 Production

OriginalPaper

Double Reactivity Against Actin and α-Actinin Defines a Severe Form of Autoimmune Hepatitis Type 1

OriginalPaper

Frequency and Clinical Manifestations of Patients with Primary Immunodeficiency Disorders in Iran: Update from the Iranian Primary Immunodeficiency Registry

OriginalPaper

Detection of Cellular Immunity to Rabies Antigens in Human Vaccinees
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits